Jana Grieb has been advising pharmaceutical and medical technology companies on all aspects of health law for over 20 years. She accompanies pharmaceuticals, medical devices, and in vitro diagnostics throughout their entire life cycle – from research and development to market access, advertising and distribution. One main area of her work is providing legal and strategic advice on market entry and reimbursement paths in the European Union, with a particular focus on the EU regulations on medical devices and in vitro diagnostics and the law governing statutory health insurance in Germany. In this context, Jana also advises on research and distribution collaborations.
Results
Jana advised:
- lifespin GmbH with regard to a research cooperation with Biobank Graz and the clinical oncology department of the medical university of Graz
- AUCTUS Capital Partners AG with regard to the sale of the PharmaLex-Group
- Myonex, Inc. in the acquisition of the clinical trials department of Hubertus Apotheke
Recognitions
- Handelsblatt/Best Lawyers™, Germany: Biotechnology Law and Life Sciences Practice, Health Care Law and Pharmaceuticals Law, 2021-2026
- Chambers Europe, Band 3 in Germany: Life Sciences, 2026
- Chambers Europe, Band 4 in Germany: Life Sciences, 2024-2025
- The Legal 500 EMEA, Recommended, Germany: Healthcare & Life Sciences, 2019-2024
- Chambers Europe, Recommended: Healthcare & Life Sciences, 2015-2023
Capabilities and Industries
Regional Markets
Community
- German Lawyers’ Association, Working Group for Medical Law
- German Federal Association for the Pharmaceutical Industry
Credentials
Education
- Nottingham Law School, LL.M.
- Higher Regional Court of Frankfurt, Second State Exam
- Universities of Gießen and Regensburg, First State Exam
Admissions
- Germania
Languages
- Inglese
- Tedesco